GlucoTrack(GCTK) - 2024 Q4 - Annual Results

Exhibit 99.1 Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...